Improving ankle movement in patients with plantar fasciitis

Observation on the Efficacy of Improving Ankle Dorsiflexion Limitation in Patients With Plantar Fasciitis

Not applicable Interventional Peking University Third Hospital · NCT06542211

This study tests a new rehabilitation program that combines regular treatment with specific exercises to see if it helps people with plantar fasciitis move their ankles better.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment40 (estimated)
Ages30 Years to 60 Years
SexAll
SponsorPeking University Third Hospital Academic / other
Locations1 site (Beijing, Beijing Municipality)
Trial IDNCT06542211 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the effectiveness of a rehabilitation program that combines conventional treatment for plantar fasciitis with targeted exercises to improve ankle dorsiflexion. The approach focuses on enhancing foot and ankle function, which is often limited in patients suffering from this condition. By comparing the outcomes of this new intervention against standard rehabilitation methods, the study seeks to determine its clinical efficacy through various evaluation indicators.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 30-60 with plantar fasciitis lasting more than 3 months and limited ankle dorsiflexion.

Not a fit: Patients who have received steroid injections in the past 3 months or have other foot conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could significantly improve mobility and quality of life for patients suffering from plantar fasciitis.

How similar studies have performed: While there is existing research on plantar fasciitis treatments, this specific combination of interventions targeting ankle dorsiflexion is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age range: 30-60 years old; disease course \> 3 months; pain cannot be relieved by conservative treatment such as rest, oral nonsteroidal drugs, and physical therapy; VAS score is less than 6 points.
2. According to the clinical practice guidelines of the International Classification of Functioning, Disability and Health: Heel Pain/Plantar Fasciitis: 2014 Revision \[16\], patients meet the clinical diagnostic criteria for PF, mainly including pain on the medial side of the plantar, heel pain caused by recent weight-bearing activities, pain on palpation of the proximal attachment of the plantar fascia, and positive Windlass test;
3. Supine straight knee ankle dorsiflexion angle \<10°; lunge knee flexion \<40° \[50, 51\]; left and right foot dorsiflexion difference does not exceed 1°.
4. BMI between 18.5-23.9 (Chinese standard)

Exclusion Criteria:

\- (1) Those who have received local injections of steroids in the past 3 months; (2) Those with other foot, ankle and lower leg diseases: history of surgery, fracture, trauma, plantar skin ulcers, rheumatism or rheumatoid arthritis, etc.; (3) Those with serious medical diseases: such as blood diseases, coagulopathy, severe cardiovascular and cerebrovascular dysfunction, tumor diseases, etc.

(4) Those with peripheral neuropathy (idiopathic, diabetic, nutritional); L5/S1 neural foramen impingement or lumbar spinal stenosis (5) Congenital structural flat feet, equinus deformity or other foot and ankle joint diseases

Where this trial is running

Beijing, Beijing Municipality

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Plantar Fasciitisankle dorisflexionplantar fasciitis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.